Humane Genomics develops precision-designed oncolytic RNA viruses that selectively infect and kill cancer cells while minimizing immunogenicity. Their platform streamlines the design, synthesis, and testing of these therapies, enabling cost-effective production and systematic delivery to target both primary tumors and metastases.
Funding
$130K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current cancer treatments often lack specificity, leading to significant side effects due to damage to healthy cells. Traditional oncolytic virus development is slow and expensive, hindering the creation of targeted therapies that can effectively eliminate cancer cells while minimizing harm to the patient.
Solution
Humane Genomics engineers precision-designed oncolytic RNA viruses that selectively target and destroy cancer cells. Their platform leverages computer-aided design, DNA synthesis, and cell transfection to streamline the development and testing of these viral therapies. The resulting viruses exhibit enhanced safety through selective infection and replication, maximizing therapeutic duration by minimizing immunogenicity. These therapies are designed for systematic delivery to address both primary tumors and metastases, while also focusing on cost-effective production for broader accessibility.
Target Audience
The primary target audience includes oncology researchers and pharmaceutical companies focused on developing novel, targeted cancer therapies with improved efficacy and reduced side effects.
Features
- Computer-aided design software for creating complex viral structures using proven building blocks.
- High-quality DNA synthesis to ensure sequence-perfect genomes.
- Cell transfection and virus testing for efficient virus production.
- Selective infection and replication mechanisms for unparalleled safety.
- Highly lytic viruses for efficient killing of cancer cells.
- Minimized immunogenicity to maximize therapeutic duration.
- Systematic delivery to treat both primary tumors and metastases.
- Cost-effective production designed with manufacturing in mind.